Patents Issued in May 2, 2019
-
Publication number: 20190125718Abstract: The specification provides compositions and methods to treat neurodegenerative diseases.Type: ApplicationFiled: December 17, 2018Publication date: May 2, 2019Inventors: Clifford J. Woolf, Brian J. Wainger, Evangelos Kiskinis, Kevin Eggan
-
Publication number: 20190125719Abstract: There is provided in accordance with an embodiment of the disclosure a spray-on composition for the treatment and prevention of insect or arachnid infestation on a mammal comprising between 0.1% and 1.0% by weight dinotefuran. There is also provided in accordance with an embodiment of the disclosure a method for treatment of an animal at risk of insect or arachnid infestation comprising topically administering to the coat of the animal a composition comprising between 1 and 50 mg dinotefuran per kilogram of animal weight. Optionally, topically administering includes spraying on a majority of the area of the coat of the animal.Type: ApplicationFiled: April 24, 2017Publication date: May 2, 2019Inventors: Amnon Vardi, Amir Kafri, Nimrod Vardi
-
Publication number: 20190125720Abstract: Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2?R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1?-cyclopropan]-2?-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody. The combination exhibits an excellent effect for treating brain tumors, and is thus useful to treat brain tumors.Type: ApplicationFiled: October 31, 2018Publication date: May 2, 2019Applicants: ONO PHARMACEUTICAL CO., LTD., The Regents of The University of CaliforniaInventors: Hideho Okada, Tohru Kotani, Kazuhiko Takeda
-
Publication number: 20190125721Abstract: The present application provides methods for treating human subjects suffering from Rett Syndrome by administering PKC activators, for example, bryostatin 1, other bryostatins and bryologs. The present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Rett syndrome a pharmaceutically effective amount of bryostatin 1.Type: ApplicationFiled: May 4, 2017Publication date: May 2, 2019Inventors: Jeffrey BENISON, Daniel L. ALKON
-
Publication number: 20190125722Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: ApplicationFiled: August 30, 2018Publication date: May 2, 2019Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLCInventors: Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
-
Publication number: 20190125723Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: June 28, 2017Publication date: May 2, 2019Applicants: Assistance Publique - Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Pierre et Marie Curie (Paris 6), Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS)Inventors: Nicolas Dupin, Anne-Geneviève Marcelin, Vincent Calvez, Philippe Grange
-
Publication number: 20190125724Abstract: The present invention targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.Type: ApplicationFiled: November 27, 2018Publication date: May 2, 2019Inventor: Steven Baranowitz
-
Publication number: 20190125725Abstract: The present invention relates to immediate release pharmaceutical compositions comprising Brivaracetam or its pharmaceutically acceptable salts, esters, solvates, derivatives, amides, polymorphs, enantiomers, prodrugs, analogues, active metabolites or mixtures thereof. The present invention also relates to a process for preparing solid oral pharmaceutical composition comprising Brivaracetam. The prior art highlights various technical challenges for the formulation development of Brivaracetam and offers restrictive and complex approach for resolution of technical challenges like use of cyclodextrin. Cyclodextrin free compositions of Brivaracetam prepared as per present invention, exhibited desirable technical attributes.Type: ApplicationFiled: May 11, 2017Publication date: May 2, 2019Inventors: Kamal Surendrakumar Mehta, Dinesh Kumar, Saurabh Srivastava
-
Publication number: 20190125726Abstract: This invention provides a pharmaceutical composition for treating or preventing synucleinopathy comprising a compound represented by formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 31, 2017Publication date: May 2, 2019Applicants: TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Kohji Fukunaga, Hiroyuki MIYACHI, Hiroaki ISHIDA, Shintaro BAN
-
Publication number: 20190125727Abstract: The invention provides compositions and methods for individualized therapy of arthritic pain without causing edema, using non-steroidal anti-inflammatory drugs (COX-2 inhibitor) in combination with a diuretic drug.Type: ApplicationFiled: October 29, 2018Publication date: May 2, 2019Applicant: Marina Biotech, Inc.Inventor: Vuong Trieu
-
Publication number: 20190125728Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: March 30, 2017Publication date: May 2, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Shuhei IKEDA, Hideyuki SUGIYAMA, Jumpei AIDA, Hidekazu TOKUHARA, Tomohiro OKAWA, Yuya OGURO, Minoru NAKAMURA, Masataka MURAKAMI
-
Publication number: 20190125729Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.Type: ApplicationFiled: October 23, 2018Publication date: May 2, 2019Inventors: John Clifford Chabala, Thomas A. Jordan, Ke-Qing Ling, John G. Gleason, William A. Kinney
-
Publication number: 20190125730Abstract: The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: October 26, 2018Publication date: May 2, 2019Inventors: Mark J. Suto, Vandana V. Gupta, Bini Mathew, Joanne Murphy-Ullrich
-
Publication number: 20190125731Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.Type: ApplicationFiled: December 18, 2018Publication date: May 2, 2019Applicant: ANGION BIOMEDICA CORP.Inventors: Bijoy PANICKER, Rama K. MISHRA, Dong Sung LIM, Lambertus J.W.M. OEHLEN, Dawoon JUNG
-
Publication number: 20190125732Abstract: A pharmaceutical composition containing an anticancer compound, named isopicrinine, isolated from the plant Rhazya Stricta. The pharmaceutical composition may contain a salt, an analog, a derivative, and/or the prodrug of isopicrinine. A method of treating cancer with the pharmaceutical composition is disclosed. A method of extracting isopicrinine is also disclosed.Type: ApplicationFiled: October 26, 2017Publication date: May 2, 2019Applicant: King Abdulaziz UniversityInventors: Jamal Sabir M. SABIR, Abdullah Y. OBAID, Nahid H. HAJRAH, Waseem MOHAMMED, Zainab H. ABDUL-HAMEED, Walied M. ALARIF, Roop Singh BORA, Seif-Eldin N. AYYAD, Nouf Saeed A. AL-ABBAS, Abdulkader M. Shaikh OMER, Mohammed Zainy MUTAWAKIL, Neil HALL, Kulvinder Singh SAINI
-
Publication number: 20190125733Abstract: The present invention relates to compositions for use in sedation and/or anesthesia, where the composition comprises MK-467 and a psychoactive drug selected from opioids, benzodiazepines, NMDA receptor antagonists and combinations thereof and the composition is administered using parenteral extravascular administration to a subject in need of sedation and/or anesthesia.Type: ApplicationFiled: May 8, 2017Publication date: May 2, 2019Applicant: VETCARE OYInventors: Outi VAINIO, Marja RAEKALLIO, Juhana HONKAVAARA, Ira KALLIO-KUJALA, Heta TURUNEN, Rachel BENNETT, Magdy ADAM
-
Publication number: 20190125734Abstract: The present invention provides a composition and a method both for treating or preventing atopic dermatitis effectively. Provided is a composition which contains an acetylcholine inhibitor, e.g., an anticholinergic substance, as an active ingredient. Also provided is a method which includes a step of administering an acetylcholine inhibitor such as an anticholinergic substance. The detailed mechanism of the development of atopic dermatitis has not been elucidated so far. Therefore, it has been difficult to treat atopic dermatitis effectively. The composition according to the present invention can treat atopic dermatitis effectively through the inhibition of the action of acetylcholine.Type: ApplicationFiled: May 9, 2017Publication date: May 2, 2019Applicant: NANOEGG Research Laboratories, Inc.Inventors: Yoko Yamaguchi, Teruaki Nagasawa, Yoshiki Kubota, Nanako Shimura, Mina Musashi
-
Publication number: 20190125735Abstract: Methods are provided for treating cancer patients who have elevated expression of FOXC2. In certain aspects, patients having elevated FOXC2 are treated with an anti-cancer therapy in conjunction with a p38 MAPK inhibitor. Methods of identifying cancer patients to be treated with p38 MAPK inhibitors are also provided. Further provided herein are methods for treating and/or preventing breast cancer metastasis by the administration of a p38 MAPK inhibitor. In certain aspects, patients are treated with an anti-cancer therapy in conjunction with a p38 MAPK inhibitor. In addition, methods are provided for the treatment of BCR-ABL positive cancers, such as acute lymphoblastic leukemia, by the administration of a p38 MAPK inhibitor and/or a glucocorticoid inhibitor in combination with a tyrosine kinase inhibitor.Type: ApplicationFiled: December 28, 2016Publication date: May 2, 2019Inventors: Sendurai A. MANI, Steven J. WERDEN, Anurag N. PARANJAPE, Rama SOUNDARARAJAN, Natalia SPHYRIS, Xiaoping SUN, Saradhi MALLAMPATI
-
Publication number: 20190125736Abstract: The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).Type: ApplicationFiled: May 24, 2017Publication date: May 2, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Alexandra RAUSCH, Stefan Joachim JODL, Jörn KRÄTZSCHMAR, Ulrich BOTHE, Nicole SCHMIDT
-
Publication number: 20190125737Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.Type: ApplicationFiled: May 31, 2018Publication date: May 2, 2019Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
-
Publication number: 20190125738Abstract: In some embodiments, methods of inhibiting, ameliorating, reducing the severity of, treating, reducing the likelihood of, or preventing social isolation stress or symptoms thereof in a subject in need thereof are described. In some embodiments, methods of determining a risk of social isolation stress in a subject are described.Type: ApplicationFiled: November 1, 2018Publication date: May 2, 2019Inventors: David J. Anderson, Moriel Zelikowsky, Andrea Choe
-
Publication number: 20190125739Abstract: Provided in the present invention is a quinoline derivative for treating gastric cancer. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt, a hydrate or a prodrug thereof as provided in the present application can effectively treat gastric cancer, and can stabilize or relieve the state of illness of a gastric cancer patient.Type: ApplicationFiled: April 14, 2017Publication date: May 2, 2019Inventors: Jie Chen, Xi Han, Hai Jiang, Xunqiang Wang
-
Publication number: 20190125740Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: ApplicationFiled: October 26, 2018Publication date: May 2, 2019Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Joseph Hofilena, Gopi Kumar Mittapalli, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Chandramouli Chiruta
-
Publication number: 20190125741Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: ApplicationFiled: October 26, 2018Publication date: May 2, 2019Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Gopi Kumar Mittapalli
-
Publication number: 20190125742Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.Type: ApplicationFiled: May 25, 2018Publication date: May 2, 2019Inventors: Bryan T. Oronsky, Jan Scicinski
-
Publication number: 20190125743Abstract: The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 3, 2016Publication date: May 2, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
-
Publication number: 20190125744Abstract: Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.Type: ApplicationFiled: December 20, 2018Publication date: May 2, 2019Applicant: Landos Biopharma, Inc.Inventors: Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
-
Publication number: 20190125745Abstract: This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.Type: ApplicationFiled: December 17, 2015Publication date: May 2, 2019Inventors: Eduardo J. MARTINEZ, Masoud Fakhr Tavazoie
-
Publication number: 20190125746Abstract: A series of novel of EHop-016 derivatives is presented herein via designing and synthesizing compounds that mimics its more favorable “U-shaped” conformation that appears to be critical for inhibitory activity against Rac. Based on modeling studies on EHop-016, compounds with a more rigid structural conformation can mimic this “U-shaped” conformation would improve the anti-migration activity against metastatic cells. Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: October 23, 2018Publication date: May 2, 2019Inventors: Eliud HERNANDEZ-O'FARRILL, Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Linette CASTILLO-PICHARDO
-
Publication number: 20190125747Abstract: Provided are solid dispersions of Compound I having the formula: wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.Type: ApplicationFiled: October 26, 2018Publication date: May 2, 2019Inventors: Hamid Rezaei, Marika Nespi, Prabha N. Ibrahim, Gary Conard Visor
-
Publication number: 20190125748Abstract: The present invention relates to a method of treating a tumor in a subject. This method involves administering to a subject having a Hippo pathway mutant tumor a tankyrase inhibitor, where the tumor is susceptible to treatment with the tankyrase inhibitor, and said administering is carried out to treat the tumor. The present invention also relates to a method of treating cancer in a subject, and a method of identifying a subject as a candidate for treatment.Type: ApplicationFiled: April 26, 2017Publication date: May 2, 2019Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Stuart A. AARONSON, Albino TROILO, Erica K. BENSON
-
Publication number: 20190125749Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4, 5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.Type: ApplicationFiled: October 24, 2018Publication date: May 2, 2019Applicant: Array BioPharma Inc.Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
-
Publication number: 20190125750Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.Type: ApplicationFiled: November 1, 2018Publication date: May 2, 2019Inventors: James D. Rodgers, Stacey Shepard
-
Publication number: 20190125751Abstract: The invention describes anti-cancer therapies comprising using a 3G-EGFR inhibitor and an irreversible (2nd generation) EGFR TKI, each as described herein.Type: ApplicationFiled: May 15, 2017Publication date: May 2, 2019Inventors: Flavio SOLCA, Mahmoud OULD KACI, Mark PETRONCZKI, Ulrike TONTSCH-GRUNT, Victoria ZAZULINA
-
Publication number: 20190125752Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.Type: ApplicationFiled: December 20, 2018Publication date: May 2, 2019Applicant: G1 Therapeutics, Inc.Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
-
Publication number: 20190125753Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or C1-C6 alkyl; ring A is cyclohexyl or phenyl, optionally substituted; ring B is aryl or a nitrogen-containing heteroaryl, optionally substituted; ring C is phenyl substituted with hydroxyl; each L1, L2 and L3 is independently C1-C6 alkyl, —CONR2— or —CONR2—X—C1-C6 alkyl-, each optionally substituted; R2 is hydrogen or C1-C6 alkyl; and X is a bond or a 5-6 membered heterocycle containing up to 3 ring heteroatoms; and methods of use such as a method for increasing hematopoiesis, for enhancing expansion of a hematopoietic stem cell (HSC), or for inhibiting an interaction between a ?-, and/or ?-catenin protein in a cell or a subject by administering a compound of Formula (I) to the subject.Type: ApplicationFiled: April 20, 2017Publication date: May 2, 2019Inventors: Yi Zhao, Michael McMillan, Yusuke Higuchi, Michael Kahn, Cu D. Nguyen
-
Publication number: 20190125754Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.Type: ApplicationFiled: December 26, 2018Publication date: May 2, 2019Inventors: Michael P. SMOLINSKI, Nader N. NASIEF ABDEL-SAYED, David G. HANGAUER, JR.
-
Publication number: 20190125755Abstract: The present invention provides a composition composed of ceftriaxone sodium and sulbactam sodium, a pharmaceutical composition comprising the same and the application thereof. The composition is characterized in that diffraction peaks at specific angles are included in the X-ray powder diffraction analysis spectrum. The pharmaceutical composition according to the present invention have better antibacterial activity and stability compared with known compositions, and are thus very suitable for the treatment of bacterial infections, especially for the treatment of refractory urogenital system infections caused by Neisseria gonorrhoeae which is drug-resistance to a variety of antibiotics (?-lactams, tetracyclines, macrolides, fluoroquinolones and aminoglycosides).Type: ApplicationFiled: November 2, 2016Publication date: May 2, 2019Applicants: XIANGBEI WELMAN PHARMACEUTICAL CO., LTD., GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD.Inventor: Mingjie SUN
-
Publication number: 20190125756Abstract: Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of desipramine or a salt thereof. The compositions include an effective amount of desipramine or a salt thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.Type: ApplicationFiled: October 30, 2018Publication date: May 2, 2019Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
-
Publication number: 20190125757Abstract: Gold(I)-carbene complexes having a selenium donor ligand with anti-cancer activity and a method of treating cancer. Methods of treating cancer comprising administering the complexes are also provided.Type: ApplicationFiled: October 26, 2017Publication date: May 2, 2019Applicant: King Fahd University of Petroleum and MineralsInventors: Adam A. A. Sulaiman, Mohammad Altaf, Anvarhusein A. Isab
-
Publication number: 20190125758Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: ApplicationFiled: December 14, 2018Publication date: May 2, 2019Inventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
-
Publication number: 20190125759Abstract: An orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg is disclosed. The dosage unit comprises (a) 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and (b) 75-99.9 wt. % of one or more pharmaceutically acceptable excipients. The solid dosage unit comprises at least 100 ?g of the estetrol component and can be obtained by a process that comprises compressing a dry blend of estetrol particles and one or more pharmaceutically acceptable excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration.Type: ApplicationFiled: July 2, 2018Publication date: May 2, 2019Applicant: Mithra Pharmaceuticals S.A.Inventors: Séverine Francine Isabelle JASPART, Johannes Jan PLATTEEUW, Denny Johan Marijn VAN DEN HEUVEL
-
Publication number: 20190125760Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.Type: ApplicationFiled: April 24, 2018Publication date: May 2, 2019Applicant: Lipocine Inc.Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
-
Publication number: 20190125761Abstract: The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.Type: ApplicationFiled: May 25, 2018Publication date: May 2, 2019Inventor: Stephen Nigel Birrell
-
Publication number: 20190125762Abstract: Injectable pharmaceutical compositions, methods of use and formulation are disclosed. The compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.Type: ApplicationFiled: December 18, 2018Publication date: May 2, 2019Inventors: Kirby Shawn Pasloske, Kai Lau, Sarah Jane Richardson, Amanda Aileen Willis
-
Publication number: 20190125763Abstract: Provided herein is a pharmaceutical composition comprising a compound having the structural formula wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.Type: ApplicationFiled: December 19, 2018Publication date: May 2, 2019Inventors: John M. MCCALL, Eric HOFFMAN, Kanneboyina NAGARAJU
-
Publication number: 20190125764Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: ApplicationFiled: December 20, 2018Publication date: May 2, 2019Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
-
Publication number: 20190125765Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.Type: ApplicationFiled: December 17, 2018Publication date: May 2, 2019Inventors: Michael B. Yaffe, Jesse C. Patterson
-
Publication number: 20190125766Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.Type: ApplicationFiled: June 26, 2018Publication date: May 2, 2019Inventors: Yair ALSTER, Omer RAFAELI, K. Angela MACFARLANE, Cary REICH, Shimon AMSELEM, Doron FRIEDMAN
-
Publication number: 20190125767Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.Type: ApplicationFiled: September 24, 2018Publication date: May 2, 2019Inventors: S. Ken Tanaka, Evangelos L. Tzanis, Lynne Garrity-Ryan, Amy L. Manley
